Literature DB >> 19506089

Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species.

Diane T Stephenson1, Tim M Coskran, Margaret B Wilhelms, Wendy O Adamowicz, Michele M O'Donnell, Kathleen B Muravnick, Frank S Menniti, Robin J Kleiman, Daniel Morton.   

Abstract

Phosphodiesterases (PDEs) comprise a family of enzymes that regulate the levels of cyclic nucleotides, key second messengers that mediate a diverse array of functions. PDE2A is an evolutionarily conserved cGMP-stimulated cAMP and cGMP PDE. In the present study, the regional and cellular distribution of PDE2A in tissues of rats, mice, cynomolgus monkeys, dogs, and humans was evaluated by immunohistochemistry. A polyclonal antibody directed to the C-terminal portion of PDE2A specifically detected PDE2A by Western blotting and by immunohistochemistry. The pattern of PDE2A immunoreactivity (ir) was consistent across all species. Western blot analysis demonstrated that PDE2A was most abundant in the brain relative to peripheral tissues. PDE2A ir was heterogeneously distributed within brain and was selectively expressed in particular peripheral tissues. In the brain, prominent immunoreactivity was apparent in components of the limbic system, including the isocortex, hippocampus, amygdala, habenula, basal ganglia, and interpeduncular nucleus. Cytoplasmic PDE2A staining was prominent in several peripheral tissues, including the adrenal zona glomerulosa, neurons of enteric ganglia, endothelial cells in all organs, lymphocytes of spleen and lymph nodes, and pituitary. These studies suggest that PDE2A is evolutionarily conserved across mammalian species and support the hypothesis that the enzyme plays a fundamental role in signal transduction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506089      PMCID: PMC2746727          DOI: 10.1369/jhc.2009.953471

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  38 in total

Review 1.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

Authors:  Celine Mehats; Carsten B Andersen; Marcello Filopanti; S L Catherine Jin; Marco Conti
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

2.  mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain.

Authors:  Wilma C G Van Staveren; Harry W M Steinbusch; Marjanne Markerink-Van Ittersum; David R Repaske; Michael F Goy; Jun Kotera; Kenji Omori; Joseph A Beavo; Jan De Vente
Journal:  J Comp Neurol       Date:  2003-12-22       Impact factor: 3.215

Review 3.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

4.  The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat.

Authors:  H W Steinbusch
Journal:  Brain Res       Date:  2001-01-12       Impact factor: 3.252

5.  Cyclic AMP metabolism by swine adipocyte microsomal and plasma membranes.

Authors:  L A Zacher; G B Carey
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  1999-09       Impact factor: 2.231

6.  Role of phosphodiesterase and protein kinase G on nitric oxide-induced inhibition of prolactin release from the rat anterior pituitary.

Authors:  M O Velardez; A De Laurentiis; M del Carmen Díaz; M Lasaga; D Pisera; A Seilicovich; B H Duvilanski
Journal:  Eur J Endocrinol       Date:  2000-08       Impact factor: 6.664

7.  cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles.

Authors:  Noriyuki Yanaka; Yukie Kurosawa; Kouichi Minami; Eri Kawai; Kenji Omori
Journal:  Biosci Biotechnol Biochem       Date:  2003-05       Impact factor: 2.043

Review 8.  Phosphodiesterase type 5 inhibition improves early memory consolidation of object information.

Authors:  Jos Prickaerts; Ayhan Sik; Wilma C G van Staveren; Guido Koopmans; Harry W M Steinbusch; Franz Josef van der Staay; Jan de Vente; Arjan Blokland
Journal:  Neurochem Int       Date:  2004-11       Impact factor: 3.921

9.  cGMP-dependent protein kinase type II regulates basal level of aldosterone production by zona glomerulosa cells without increasing expression of the steroidogenic acute regulatory protein gene.

Authors:  Stepan Gambaryan; Elke Butt; Katrin Marcus; Margarita Glazova; Alois Palmetshofer; Gilles Guillon; Albert Smolenski
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more
  28 in total

1.  First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430.

Authors:  Mika Naganawa; Rikki N Waterhouse; Nabeel Nabulsi; Shu-Fei Lin; David Labaree; Jim Ropchan; Sanela Tarabar; Nicholas DeMartinis; Adam Ogden; Anindita Banerjee; Yiyun Huang; Richard E Carson
Journal:  J Nucl Med       Date:  2016-04-21       Impact factor: 10.057

2.  Transcriptome analysis reveals differentially expressed transcripts in rat adrenal zona glomerulosa and zona fasciculata.

Authors:  Koshiro Nishimoto; Christine S Rigsby; Tao Wang; Kuniaki Mukai; Celso E Gomez-Sanchez; William E Rainey; Tsugio Seki
Journal:  Endocrinology       Date:  2012-02-28       Impact factor: 4.736

Review 3.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 4.  Phosphodiesterases and adrenal Cushing in mice and humans.

Authors:  E Szarek; C A Stratakis
Journal:  Horm Metab Res       Date:  2014-09-18       Impact factor: 2.936

5.  Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme.

Authors:  Laigao Chen; Nabeel Nabulsi; Mika Naganawa; Kenneth Zasadny; Marc B Skaddan; Lei Zhang; Soheila Najafzadeh; Shu-Fei Lin; Christopher J Helal; Tracey L Boyden; Cheng Chang; Jim Ropchan; Richard E Carson; Anabella Villalobos; Yiyun Huang
Journal:  J Nucl Med       Date:  2016-05-19       Impact factor: 10.057

6.  Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats.

Authors:  Jun-Nan Wang; Xue-Jun Zhao; Zhi-Hua Liu; Xu-Li Zhao; Tao Sun; Zhi-Jian Fu
Journal:  Eur Spine J       Date:  2017-03-10       Impact factor: 3.134

7.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

8.  The distribution of phosphodiesterase 2A in the rat brain.

Authors:  D T Stephenson; T M Coskran; M P Kelly; R J Kleiman; D Morton; S M O'Neill; C J Schmidt; R J Weinberg; F S Menniti
Journal:  Neuroscience       Date:  2012-09-19       Impact factor: 3.590

Review 9.  Targeting phosphodiesterases in anti-platelet therapy.

Authors:  Matthew T Rondina; Andrew S Weyrich
Journal:  Handb Exp Pharmacol       Date:  2012

10.  Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease.

Authors:  Reagan Farmer; Steven D Burbano; Neema S Patel; Angelo Sarmiento; Abigail J Smith; Michy P Kelly
Journal:  Cell Signal       Date:  2020-02-29       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.